Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
Total Valuation
Design Therapeutics has a market cap or net worth of $551.41M. The enterprise value is -$22.71M.
Market Cap$551.41M
Enterprise Value-$22.71M
Share Statistics
Design Therapeutics has 56,963,757 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding56,963,757
Owned by Insiders18.52%
Owned by Institutions37.54%
Financial Efficiency
Design Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -25.44%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-25.44%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee0.00
Profits Per Employee-885.50K
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Design Therapeutics is ―. Design Therapeutics’s PEG ratio is 0.27.
PE Ratio―
PS Ratio0.00
PB Ratio1.44
Price to Fair Value1.44
Price to FCF-8.04
Price to Operating Cash Flow-8.34
PEG Ratio0.27
Income Statement
In the last 12 months, Design Therapeutics had revenue of 0.00 and earned -49.59M in profits. Earnings per share was -0.88.
Revenue0.00
Gross Profit-596.00K
Operating Income-62.38M
Pretax Income-49.59M
Net Income-49.59M
EBITDA-48.99M
Earnings Per Share (EPS)-0.88
Cash Flow
In the last 12 months, operating cash flow was -52.25M and capital expenditures -159.00K, giving a free cash flow of -52.41M billion.
Operating Cash Flow-52.25M
Free Cash Flow-52.41M
Free Cash Flow per Share-0.92
Dividends & Yields
Design Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.25
52-Week Price Change60.39%
50-Day Moving Average7.81
200-Day Moving Average5.35
Relative Strength Index (RSI)62.52
Average Volume (3m)213.56K
Important Dates
Design Therapeutics upcoming earnings date is Mar 17, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 17, 2026
Ex-Dividend Date―
Financial Position
Design Therapeutics as a current ratio of 29.31, with Debt / Equity ratio of 0.52%
Current Ratio29.31
Quick Ratio29.31
Debt to Market Cap<0.01
Net Debt to EBITDA0.41
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Design Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Design Therapeutics EV to EBITDA ratio is -6.71, with an EV/FCF ratio of -7.57.
EV to Sales0.00
EV to EBITDA-6.71
EV to Free Cash Flow-7.57
EV to Operating Cash Flow-7.63
Balance Sheet
Design Therapeutics has $205.97M in cash and marketable securities with $1.74M in debt, giving a net cash position of $204.23M billion.
Cash & Marketable Securities$205.97M
Total Debt$1.74M
Net Cash$204.23M
Net Cash Per Share$3.59
Tangible Book Value Per Share$4.28
Margins
Gross margin is -28.91%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-28.91%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Design Therapeutics is $14.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.00
Price Target Upside56.60% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-40.26%